Wall Street analysts are accelerating the rise in Microsoft (MSFT) stock thanks to recent calls from the market’s top analysts. Microsoft stock has risen 17.9% since the beginning of the year, driven by strong demand for the company’s Azure cloud and AI services. The company has entered into a new partnership with INBRAIN Neuroelectronics to bring the power of AI to healthcare.
INBRAIN is working on a suite of graphene-based neural technologies and is looking to Microsoft for agent-based artificial intelligence (AI) tools. Being based on Azure allows the INBRAIN platform to learn and adapt to individual patients. MSFT shares rose on Monday on the news, with the stock up 20% year-to-date. Additionally, MSFT is trading near the top of its 52-week range and above its 200-day simple moving average.
“Our collaboration with Microsoft combines our high-precision graphene neural technology with one of the most powerful AI ecosystems in the world,” said Carolina Aguilar, co-founder and CEO of INBRAIN. “This partnership brings us closer to a future where brain-computer interfaces go beyond simply deciphering and modulating the nervous system to truly understanding and responding to the nervous system in real time, where the nervous system becomes the body’s operating system.”
Microsoft (MSFT) is also on the rise after the company started selling its Copilot AI chatbot through social media influencers. Microsoft launched this campaign to attract a younger audience and improve its position in the rapidly growing AI industry. Yusuf Mehdi, consumer marketing leader at Microsoft, said influencer marketing is more effective than advertising. “These collaborations show what Copilot can do in real life in a way that people can relate to,” he said.
Analysts believe that Microsoft stock has the potential to rise, with all major analysts rating Microsoft stock an “outperform” or “buy” rating. Target prices range from $600 to $650, indicating optimism for future growth compared to the current market price of $505.
